Study protocol: azithromycin therapy for chronic lung disease of prematurity (AZTEC) - a randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants
Introduction Chronic lung disease of prematurity (CLD), also known as bronchopulmonary dysplasia (BPD), is a cause of significant respiratory morbidity in childhood and beyond. Coupled with lung immaturity, infections (especially by Ureaplasma spp) are implicated in the pathogenesis of CLD through p...
Main Authors: | John Lowe, Marie Hubbard, Janet Berrington, Sailesh Kotecha |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-10-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/10/e041528.full |
Similar Items
-
Azithromycin versus placebo for the treatment of HIV-associated chronic lung disease in children and adolescents (BREATHE trial): study protocol for a randomised controlled trial
by: Carmen Gonzalez-Martinez, et al.
Published: (2017-12-01) -
Oxidants and antioxidants in the pathogenesis of chronic lung disease of prematurity
by: Vyas, Julian Ramesh
Published: (2003) -
Reducing the incidence of chronic lung disease in very premature infants with aminophylline
by: Amir-Mohammad Armanian, et al.
Published: (2014-01-01) -
Chronic prostatitis: The role of Azithromycin
by: Lin-Nei Hsu, et al.
Published: (2016-06-01) -
Macrophage phenotype is associated with disease severity in preterm infants with chronic lung disease.
by: Lynne R Prince, et al.
Published: (2014-01-01)